Thiazolidinedione drugs in the treatment of type 2 diabetes mellitus: past, present and future
- PMID: 28816105
- DOI: 10.1080/10408444.2017.1351420
Thiazolidinedione drugs in the treatment of type 2 diabetes mellitus: past, present and future
Abstract
Thiazolidinedione (TZD) drugs used in the treatment of type 2 diabetes mellitus (T2DM) have proven effective in improving insulin sensitivity, hyperglycemia, and lipid metabolism. Though well tolerated by some patients, their mechanism of action as ligands of peroxisome proliferator-activated receptors (PPARs) results in the activation of several pathways in addition to those responsible for glycemic control and lipid homeostasis. These pathways, which include those related to inflammation, bone formation, and cell proliferation, may lead to adverse health outcomes. As treatment with TZDs has been associated with adverse hepatic, cardiovascular, osteological, and carcinogenic events in some studies, the role of TZDs in the treatment of T2DM continues to be debated. At the same time, new therapeutic roles for TZDs are being investigated, with new forms and isoforms currently in the pre-clinical phase for use in the prevention and treatment of some cancers, inflammatory diseases, and other conditions. The aims of this review are to provide an overview of the mechanism(s) of action of TZDs, a review of their safety for use in the treatment of T2DM, and a perspective on their current and future therapeutic roles.
Keywords: Thiazolidinedione; adverse effects; bone fracture; cancer; diabetes; drug safety; heart failure; hepatotoxicity; mechanism; myocardial infarction.
Similar articles
-
The future of thiazolidinedione therapy in the management of type 2 diabetes mellitus.Curr Diab Rep. 2013 Jun;13(3):329-41. doi: 10.1007/s11892-013-0378-8. Curr Diab Rep. 2013. PMID: 23625197 Review.
-
Does Thiazolidinedione therapy exacerbate fluid retention in congestive heart failure?Pharmacol Ther. 2016 Dec;168:75-97. doi: 10.1016/j.pharmthera.2016.09.007. Epub 2016 Sep 4. Pharmacol Ther. 2016. PMID: 27598860 Review.
-
Thiazolidinediones and PPARγ agonists: time for a reassessment.Trends Endocrinol Metab. 2012 May;23(5):205-15. doi: 10.1016/j.tem.2012.03.001. Epub 2012 Apr 17. Trends Endocrinol Metab. 2012. PMID: 22513163 Review.
-
The current role of thiazolidinediones in diabetes management.Arch Toxicol. 2016 Aug;90(8):1861-81. doi: 10.1007/s00204-016-1737-4. Epub 2016 May 10. Arch Toxicol. 2016. PMID: 27165418 Review.
-
Peroxisome Proliferator-Activated Receptors as Superior _targets for Treating Diabetic Disease, Design Strategies - Review Article.Turk J Pharm Sci. 2022 Jun 27;19(3):353-370. doi: 10.4274/tjps.galenos.2021.70105. Turk J Pharm Sci. 2022. PMID: 35775494 Free PMC article.
Cited by
-
Association between Parkinson's Disease and Diabetes Mellitus: From Epidemiology, Pathophysiology and Prevention to Treatment.Aging Dis. 2022 Dec 1;13(6):1591-1605. doi: 10.14336/AD.2022.0325. eCollection 2022 Dec 1. Aging Dis. 2022. PMID: 36465171 Free PMC article.
-
Reflections on the state of diabetes research and prospects for treatment.Diabetol Int. 2022 Sep 7;14(1):21-31. doi: 10.1007/s13340-022-00600-2. eCollection 2023 Jan. Diabetol Int. 2022. PMID: 36636157 Free PMC article. Review.
-
Molecules Isolated from Mexican Hypoglycemic Plants: A Review.Molecules. 2020 Sep 10;25(18):4145. doi: 10.3390/molecules25184145. Molecules. 2020. PMID: 32927754 Free PMC article. Review.
-
A double-blind, Randomized controlled trial on glucose-lowering EFfects and safety of adding 0.25 or 0.5 mg lobeglitazone in type 2 diabetes patients with INadequate control on metformin and dipeptidyl peptidase-4 inhibitor therapy: REFIND study.Diabetes Obes Metab. 2022 Sep;24(9):1800-1809. doi: 10.1111/dom.14766. Epub 2022 Jun 9. Diabetes Obes Metab. 2022. PMID: 35581902 Free PMC article. Clinical Trial.
-
Anti-Diabetic Drugs: Cure or Risk Factors for Cancer?Pathol Oncol Res. 2018 Oct;24(4):745-755. doi: 10.1007/s12253-018-0402-z. Epub 2018 Mar 13. Pathol Oncol Res. 2018. PMID: 29536373 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous